Pharmagen Stock Price Prediction
| PHRX Stock | USD 0.00001 0.00 0.00% |
Momentum 0
Sell Peaked
Oversold | Overbought |
Wall Street Target Price 0.13 | Quarterly Revenue Growth (0.23) |
Using Pharmagen hype-based prediction, you can estimate the value of Pharmagen from the perspective of Pharmagen response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Pharmagen to buy its stock at a price that has no basis in reality. In that case, they are not buying Pharmagen because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Pharmagen after-hype prediction price | USD 1.0E-5 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Pharmagen |
Pharmagen After-Hype Price Prediction Density Analysis
As far as predicting the price of Pharmagen at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Pharmagen or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Pharmagen, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Pharmagen Estimiated After-Hype Price Volatility
In the context of predicting Pharmagen's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Pharmagen's historical news coverage. Pharmagen's after-hype downside and upside margins for the prediction period are 0.00 and 13.02, respectively. We have considered Pharmagen's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Pharmagen is out of control at this time. Analysis and calculation of next after-hype price of Pharmagen is based on 3 months time horizon.
Pharmagen Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Pharmagen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pharmagen backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Pharmagen, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.69 | 13.02 | 0.00 | 0.01 | 0 Events / Month | 1 Events / Month | Within a week |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.00001 | 0.00001 | 0.00 |
|
Pharmagen Hype Timeline
Pharmagen is at this time traded for 0.00001. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.01. Pharmagen is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is projected to be very small, whereas the daily expected return is at this time at -1.69%. %. The volatility of related hype on Pharmagen is about 260400.0%, with the expected price after the next announcement by competition of -0.01. The company had not issued any dividends in recent years. Pharmagen had 45:1 split on the 7th of December 2011. Given the investment horizon of 90 days the next projected press release will be within a week. Check out Pharmagen Basic Forecasting Models to cross-verify your projections.Pharmagen Related Hype Analysis
Having access to credible news sources related to Pharmagen's direct competition is more important than ever and may enhance your ability to predict Pharmagen's future price movements. Getting to know how Pharmagen's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Pharmagen may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| AHG | Akso Health Group | (0.03) | 6 per month | 4.91 | 0.01 | 9.22 | (8.94) | 41.30 | |
| NSRS | North Springs Resources | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| PDMI | Paradigm Medical Ind | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SCIE | Spectrascience New | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ITNS | Itonis Inc | 0.00 | 0 per month | 7.90 | 0.03 | 33.33 | (25.00) | 58.33 | |
| NPHC | Nutra Pharma Corp | 0.00 | 0 per month | 0.00 | 0.12 | 0.00 | 0.00 | 100.00 |
Pharmagen Additional Predictive Modules
Most predictive techniques to examine Pharmagen price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Pharmagen using various technical indicators. When you analyze Pharmagen charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Pharmagen Predictive Indicators
The successful prediction of Pharmagen stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Pharmagen, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Pharmagen based on analysis of Pharmagen hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Pharmagen's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Pharmagen's related companies. | 2010 | 2024 | 2025 (projected) | |
| Inventory Turnover | 12.91 | 11.62 | 10.33 |
| ROIC | 0.79 | 0.71 | 0.63 |
Story Coverage note for Pharmagen
The number of cover stories for Pharmagen depends on current market conditions and Pharmagen's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Pharmagen is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Pharmagen's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Additional Tools for Pharmagen Stock Analysis
When running Pharmagen's price analysis, check to measure Pharmagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmagen is operating at the current time. Most of Pharmagen's value examination focuses on studying past and present price action to predict the probability of Pharmagen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmagen's price. Additionally, you may evaluate how the addition of Pharmagen to your portfolios can decrease your overall portfolio volatility.